Short-Term, Weight-Adjusted Colchicine to Prevent Post-CABG Arrhythmias: A Randomized, Double-Blind, Controlled Trial.
Pacing Clin ElectrophysiolMay 14, 2026 (epub)
Amir Hassan Farzaneh, Hamideh Abbaspour, Valiollah Habibi et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, controlled trial evaluated the efficacy and safety of short-term, weight-adjusted colchicine in preventing postoperative atrial fibrillation (POAF) in 172 adults undergoing CABG. The colchicine group had a significantly lower incidence of POAF at 17.3% compared to 46.3% in the placebo group (RR 0.37, p < 0.001).
Key findings
- Colchicine reduced POAF incidence to 17.3% compared to 46.3% in the placebo group.
- The absolute risk reduction for POAF was 29.0%, with a number needed to treat of 4.
- Colchicine significantly reduced both early and late POAF (p < 0.001 and p = 0.002).
- Gastrointestinal events occurred more frequently with colchicine (25.9% vs 8.5%, p = 0.003).
Why it matters
Postoperative atrial fibrillation is a common complication after CABG, associated with adverse outcomes. Effective prevention strategies, such as colchicine, can improve patient recovery and reduce hospital stays.